To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have MIDD/LCDD or amyloidosis.
- Patients may not have already been treated for the disease, with the exception of one cycle of dexamethasone.
- Patients may not have had prior treatment with bortezomib.
- At least 3 weeks must have passed since completion of any prior radiation therapy.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Hani Hassoun at 212-639-3228.